Resultados de la búsqueda 171-180 of 2802 for ������������KA���:ZA31���24������ ���������������������������������
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...
Create a registry of patients having or at risk for cancer of the liver or bile ducts (also known as hepatocellular carcinoma or cholangiocarcinoma), or ...
Rochester, Minn. The purpose of this study is to attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation ...
Levels of bladder cancer-derived extracellular vesicles become undetectable after radical cystectomy in patients with localized bladder cancer. This study hopes ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
The purpose of this study is to assess the differences in microvascular anastomosis outcomes between the experiment aneurysmal subarachnoid hemorrhage (aSAH)- ...
1) Develop hypotheses related to how the human genome and genetic variants affect hearing loss in children and adults. 2) Understand phenotypes of hearing loss ...
Many of the current imaging tests we have for prostate cancer are problematic in their ability to distinguish cancerous from non-cancerous prostate tissue. This ...
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
The objective of this study is to evaluate the image quality and radiation dose of a CT angiography protocol (CTA) using tube potential selection and weight- ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?